Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the efficacy and safety of neoadjuvant pembrolizumab plus
chemotherapy in resectable locally advanced esophageal squamous cell carcinoma patients